Zisis Bimpisidis
University of Cagliari
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Zisis Bimpisidis.
Frontiers in Psychiatry | 2014
Maria Antonietta De Luca; Valentina Valentini; Zisis Bimpisidis; Pierluigi Caboni; Gaetano Di Chiara
2-Arachidonoylglycerol (2-AG) is the most potent endogenous ligand of brain cannabinoid CB1 receptors and is synthesized on demand from 2-arachidonate-containing phosphoinositides by the action of diacylglycerol lipase in response to increased intracellular calcium. Several studies indicate that the endocannabinoid (eCB) system is involved in the mechanism of reward and that diverse drugs of abuse increase brain eCB levels. In addition, eCB are self-administered (SA) by squirrel monkeys, and anandamide increases nucleus accumbens (NAc) shell dopamine (DA) in rats. To date, there is no evidence on the reinforcing effects of 2-AG and its effects on DA transmission in rodents. In order to fill this gap, we studied intravenous 2-AG SA and monitored the effect of 2-AG on extracellular DA in the NAc shell and core via microdialysis in male Sprague-Dawley rats. Rats were implanted with jugular catheters and trained to self-administer 2-AG [25 mg/kg/inf intravenously (iv)] in single daily 1 h sessions for 5 weeks under initial fixed ratio (FR) 1 schedule. The ratio was subsequently increased to FR2. Active nose poking increased from the 6th SA session (acquisition phase) but no significant increase of nose pokes was observed after FR2. When 2-AG was substituted for vehicle (25th SA session, extinction phase), rate responding as well as number of injections slowly decreased. When vehicle was replaced with 2-AG, SA behavior immediately recovered (reacquisition phase). The reinforcing effects of 2-AG in SA behavior were fully blocked by the CB1 receptor inverse agonist/antagonist rimonabant (1 mg/kg intraperitoneally, 30 min before SA session). In the microdialysis studies, we observed that 2-AG (0.1–1.0 mg/kg iv) preferentially stimulates NAc shell as compared to the NAc core. NAc shell DA increased by about 25% over basal value at the highest doses tested (0.5 and 1.0 mg/kg iv). The results obtained suggest that the eCB system, via 2-AG, plays an important role in reward.
International Journal of Pharmaceutics | 2015
Maria Antonietta De Luca; Francesco Lai; Francesco Corrias; Pierluigi Caboni; Zisis Bimpisidis; Elias Maccioni; Anna Maria Fadda; Gaetano Di Chiara
The aim of this work was to evaluate the capability of lactoferrin- and antitransferrin-modified long circulating liposomes to deliver the hydrophilic peptide senktide, a selective NK3 receptor agonist unable to cross the blood brain barrier, to central nervous system by using an indirect method based on in vivo microdialysis studies to estimate the responsiveness of nucleus accumbens shell dopamine to senktide. To this purpose, senktide was encapsulated in different targeted and not-targeted stealth liposomes prepared using film hydration method. Formulations were characterized in terms of morphology, size distribution, zeta potential, encapsulation efficiency, and antibody presence on the liposome surface. In vivo microdialysis studies were performed injecting intravenously the senktide-loaded liposomes and comparing obtained dopamine levels with those found with the free senktide given intracerebroventricularly. Results showed that all vesicles were spherical, small in size (around 120 nm), homogeneously dispersed, and slightly negatively charged. TEM analysis, using an anti IgG secondary antibody with 10nm gold nanoparticles at its distal end, demonstrated the successful linkage of the antibody on the liposomal surface. Intravenously administered in rats, senktide-loaded targeted stealth liposomes elicited a significant increase of dialysate dopamine in the nucleus accumbens shell, which was comparable to that of the free senktide given intracerebroventricularly when antitransferrin-targeted liposomes were tested. On the contrary, control stealth liposomes did not affect dopamine levels. Senktide brain levels were higher using the antitransferrin-targeted liposomes in comparison with the lactoferrin ones, while the opposite was obtained in the liver tissue where the highest senktide accumulation was always found.
European Journal of Neuroscience | 2013
Zisis Bimpisidis; Maria Antonietta De Luca; Augusta Pisanu; Gaetano Di Chiara
Taste stimuli increase extracellular dopamine (DA) in the nucleus accumbens (NAc) and in the medial prefrontal cortex (mPFC). This effect shows single‐trial habituation in NAc shell but not in core or in mPFC. Morphine sensitization abolishes habituation of DA responsiveness in NAc shell but induces it in mPFC. These observations support the hypothesis of an inhibitory influence of mPFC DA on NAc DA. To test this hypothesis, we used in vivo microdialysis to investigate the effect of mPFC 6‐hydroxy‐dopamine (6‐OHDA) lesions on the NAc DA responsiveness to taste stimuli. 6‐OHDA was infused bilaterally in the mPFC of rats implanted with guide cannulae. After 1 week, rats were implanted with an intraoral catheter, microdialysis probes were inserted into the guide cannulae, and dialysate DA was monitored in NAc shell/core after intraoral chocolate. 6‐OHDA infusion reduced tissue DA in the mPFC by 75%. Tyrosine hydroxylase immunohistochemistry showed that lesions were confined to the mPFC. mPFC 6‐OHDA lesion did not affect the NAc shell DA responsiveness to chocolate in naive rats but abolished habituation in rats pre‐exposed to the taste. In the NAc core, mPFC lesion potentiated, delayed and prolonged the stimulatory DA response to taste but failed to affect DA in pre‐exposed rats. Behavioural taste reactions and motor activity were not affected. The results indicate a top‐down control of NAc DA by mPFC and a reciprocal relationship between DA transmission in these two areas. Moreover, habituation of DA responsiveness in the NAc shell is dependent upon an intact DA input to the mPFC.
Neuropharmacology | 2012
M.A. De Luca; Marcello Solinas; Zisis Bimpisidis; Steven R. Goldberg; G. Di Chiara
Neuropharmacology | 2015
M.A. De Luca; Zisis Bimpisidis; Miriam Melis; Matteo Marti; Pierluigi Caboni; Valentina Valentini; Giulia Margiani; Nicholas Pintori; I. Polis; Giovanni Marsicano; Loren H. Parsons; G. Di Chiara
Psychopharmacology | 2011
Maria Antonietta De Luca; Zisis Bimpisidis; Valentina Bassareo; Gaetano Di Chiara
42nd Annual Meeting of the Society-for-Neuroscience | 2012
Maria Antonietta De Luca; Pierluigi Caboni; Zisis Bimpisidis; Valentina Valentini; Matteo Marti; G. Di Chiara
Archive | 2018
Zisis Bimpisidis; Liana Fattore; Maria Antonietta De Luca
8th IBRO World Congress of Neuroscience | 2011
Zisis Bimpisidis; Maria Antonietta De Luca; Valentina Valentini; G. Di Chiara
7th FENS forum of European Neuroscience | 2010
Maria Antonietta De Luca; Valentina Valentini; Zisis Bimpisidis; Pierluigi Caboni; G. Di Chiara